A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT00514371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2/3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Comparing Three Doses of Tanespimycin in Patients With Relapsed-Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT00514371
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Interventions
- Bortezomib Drug
- tanespimycin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2007
- Primary completion
- Jan 31, 2009
- Completion
- Jan 31, 2009
- Last update posted
- Dec 6, 2015
2007 – 2009
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Berkeley | California | 94704 | — |
| Local Institution | San Francisco | California | 94143 | — |
| Local Institution | Augusta | Georgia | 30912 | — |
| Local Institution | Baltimore | Maryland | 21201 | — |
| Local Institution | Boston | Massachusetts | 02215 | — |
| Local Institution | Omaha | Nebraska | 68114 | — |
| Local Institution | New York | New York | 10011 | — |
| Local Institution | New York | New York | 10021 | — |
| Local Institution | Winston-Salem | North Carolina | 27157 | — |
| Local Institution | Pittsburgh | Pennsylvania | 15224 | — |
| Local Institution | Columbia | South Carolina | 29210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00514371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2015 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00514371 live on ClinicalTrials.gov.